What is the current price for "Will the FDA approve MDMA for PTSD?"?

The leading outcome "Yes" is currently trading at 54.5% probability.

How many markets are available for "Will the FDA approve MDMA for PTSD?"?

There are 6 markets available for this event on Kalshi.

What is the trading volume for "Will the FDA approve MDMA for PTSD?"?

Trading volume data is not currently available.

BackKKALSHI

Will the FDA approve MDMA for PTSD?

Yes54%

Vol$0.00

Markets6

54%

TradeTrade on Kalshi

Event Group

EventKALSHI

Single EventKALSHIScience and Technology

Will the FDA approve MDMA for PTSD?

Name: Will the FDA approve MDMA for PTSD?
Start: 2026-07-10T06:50:46.170Z
End: 2026-08-09T06:50:46.170Z

Part of: Will the FDA approve MDMA for PTSD?

MDMA for PTSD If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, X then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug App

YesLeading Yes Probability

54%

VolTotal Volume

$0.00

Markets

Trade on Kalshi

Will the FDA approve MDMA for PTSD?

Yes

54%

Vol

$0.00

Markets

Trade

Market Price Graph

6 markets tracked

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2032?

kalshi

No data available

All Markets(6)

Market	Price
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2032?	54%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031?	52%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?	49%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2029?	46%
Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2028?	38%

Markets (6)

Sort

KALSHIHealth

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2032?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2032, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-mar

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2031?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2031, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-mar

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2030?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2030, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-mar

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2029?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2029, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-mar

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2028?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2028, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-mar

Will the FDA approve midomafetamine / MDMA for PTSD before Jan 1, 2027?

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes. Secondary rules: An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-mar